On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

On Tuesday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $69.91 which represents a decrease of $-0.22 or -0.31% from the prior close of $70.13. The stock opened at $69.78 ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Joseph Schwartz has ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

(BMRN) on Tuesday reported third-quarter earnings of $106.1 million. The San Rafael, California-based company said it had profit of 55 cents per share. Earnings, adjusted for one-time gains and costs, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...